Hans A Eriksson, MD, PhD, MBA

Trials

Studies that name Hans A Eriksson, MD, PhD, MBA as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:30 UTC. Open this list on ClinicalTrials.gov

• Ph1
  NCT01403922 · To Determine Blood Pressure Interaction Between TC-5214 and Anti-Hypertensive Medications (Calcium Channel Blockers, Beta Blockers, and ACE Inhibitors) in Patients With Chronic Hypertension

  AstraZeneca · terminated · Chronic Hypertension · study director
• Ph1
  NCT01359618 · Determining Highest Dose Administration of TC-5214 and Evaluating Effect on the Electrical Activity in the Heart

  AstraZeneca · terminated · Healthy Male · study director
• Ph2
  NCT01288079 · A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.

  AstraZeneca · terminated · Major Depressive Disorder · study director
• Ph3
  NCT01197508 · A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder.

  AstraZeneca · completed · Major Depressive Disorder · study director
• Ph3
  NCT01153347 · A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder

  AstraZeneca · completed · Major Depressive Disorder, Depression · study director

Grants

NIH projects from RePORTER, fetched 2026-11-12 11:30 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.